A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia

Phase 2 Terminated 40 enrolled LigaChem Biosciences, Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

The objectives of this study is to exploratory whether Vancomycin + Delpazolid is more effective to the standard of treatment (Vancomycin)/ for hospitalized adults with MRSA bacteraemia.

Timeline

Start: 2022-04-26
Primary completion: 2024-02-21
Completion: 2024-03-18

Outcome

Missed primary endpoint

Stopped (Enrollment): “Early termination; Difficulties in enrolling subjects due to the decrease in patients with MRSA bacteremia”

paper On day 14, overall cure was 52.6% in the monotherapy and 60.0% in the combination group (P = 0.6675). PMID 41705840 ↗

Publications

Park K-H, Jung J, Shin SU, Jeong SJ, Park DW, Kim D-M, Choi SJ, Moon SM, Park JS, Song K-H, Kim ES, Cho YL, Bae S, Kim HB; Korea INfectious Diseases (KIND) Study Group. Preclinical and clinical evaluation of vancomycin plus delpazolid combination therapy for MRSA bacteremia: a multicenter, double-blinded, randomized, parallel design, phase IIa clinical trial. Microbiol Spectr. 2026 Apr 7;14(4):e0336125. doi: 10.1128/spectrum.03361-25. Epub 2026 Feb 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Delpazolid	Small molecule	800 mg	Oral
Subject	Vancomycin	Other / unclassified	15 mg/kg	Intravenous
Subject	Vancomycin	Other / unclassified	20 mg/kg	Intravenous